

JENKINS  
WILSON  
& TAYLOR

patent attorneys

March 3, 2004



I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on March 3, 2004.

*Patty Wilson*  
Patty Wilson  
Date of Signature: March 3, 2004

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Re: U.S. Patent Application Serial No. 10/716,204 for  
LIPOXYGENASE PROTEINS AND NUCLEIC ACIDS  
Our Ref. No. 1242/5/2/2

Sir:

Please find enclosed in connection with the subject U.S. patent application the following documents:

1. Information Disclosure Statement (2 pages);
2. Form PTO/SB/08A and PTO/SB/08B (2 pages); and
3. A return-receipt postcard to be returned to us with the U.S. Patent and Trademark Office filing stamp thereon.

The Commissioner is hereby authorized to charge any fees associated with the filing of this correspondence to Deposit Account No. **50-0426**.

Respectfully submitted,

JENKINS, WILSON & TAYLOR, P.A.

Arles A. Taylor, Jr.  
Registration No. 39,395

AAT/ptw  
Enclosures  
Customer No: 25297

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on March 3, 2004.



Betty Wilson  
Date of Signature March 3, 2004

**PATENT**

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Brash et al.

Group Art Unit: 1652

**Serial No.: 10/716,204**

Examiner: Tung, P.

Filed: November 18, 2003

Docket No.: 1242/5/2/2

For: LIPOXYGENASE PROTEINS AND NUCLEIC ACIDS

\*\*\*\*\*

**INFORMATION DISCLOSURE STATEMENT**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

In accordance with 37 C.F.R. 1.56, 1.97, and 1.98, applicants' undersigned attorney brings to the attention of the Patent and Trademark Office the following references. Forms PTO/SB/08A and PTO/SB/08B are attached hereto.

Copies of the cited documents are of record in the file history of U.S. Patent Application Serial No. 09/764,246 filed on January 17, 2001. The above-captioned application claims priority to U.S. Patent Application Serial No. 09/764,246 under 35 U.S.C. § 120, and as per 37 C.F.R. § 1.98, no copies of these cited documents are believed to be required.

Early passage of the subject application to issue is earnestly solicited.


Serial No.: 10/716,204

Although it is believed that no fee is due, the Commissioner is hereby authorized to charge any fees associated with the filing of this correspondence to Deposit Account No. 50-0426.

Respectfully submitted,

JENKINS, WILSON & TAYLOR, P.A.

Date: 03/03/2004

By:   
Arles A. Taylor, Jr.  
Registration No. 39,395

1242/5/2/2          AAT/ptw

Enclosures

Customer No: 25297

+

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE


Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

**Complete if Known**

*(use as many sheets as necessary)*

Sheet	1	of	1
-------	---	----	---

<b>Application Number</b>	10/716,204
<b>Filing Date</b>	11/18/2003
<b>First Named Inventor</b>	Alan R. Brash
<b>Group Art Unit</b>	
<b>Examiner Name</b>	.
<b>Attorney Docket Number</b>	1242/5/2/2

[illegible][illegible]

Examiner  
Signature

Date	
Considered	

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

**Burden Hour Statement:** This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.**

Please type a plus sign (+) inside this box → +

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO  <h2 style="text-align: center; margin: 0;">INFORMATION DISCLOSURE STATEMENT BY APPLICANT</h2> <p style="text-align: center; margin: 5px 0;"><i>(use as many sheets as necessary)</i></p>		Complete if Known	
		Application Number	10/716,204
		Filing Date	11/18/2003
		First Named Inventor	Alan R. Brash
		Group Art Unit	
		Examiner Name	
		Attorney Docket Number	1242/5/2/2
Sheet	1	of	1

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	C1	BRASH ET AL., "Discovery of a Second 15S-lipoxygenase in Humans," Proc. Natl. Acad. Sci. USA, Vol. 94, p. 6148-6152, (1997).	X
	C2	FUNK ET AL., "Native and Mutant 5-lipoxygenase Expression in a Baculovirus/Insect Cell System," Proc. Natl. Acad. Sci. USA, Vol. 86, p. 2592-2596, (1989).	X
	C3	FURSTENBERGER ET AL., "Characterization of an 8-Lipoxygenase Activity Induced by the Phorbol Ester Tumor Promoter 12-O-Tetradecanoylphorbol-13-acetate in Mouse Skin in Vivo," J. Biol. Chem., Vol. 266 (No. 24), p. 15738-15745, (1991).	X
	C4	JISAKA ET AL., "Molecular Cloning and Functional Expression of a Phorbol Ester-inducible 8S-Lipoxygenase from Mouse Skin," J. Biol. Chem., Vol. 272 (No. 26), p. 24410-24416, (1997).	X
	C5	KRIEG ET AL., "cDNA Cloning of a 8-Lipoxygenase and a Novel Epidermis-type Lipoxymgenase from Phorbol Ester-treated Mouse Skin," Biochim. Biophys. Acta, Vol. 1391, p. 7-12, (1998).	X
	C6	LEE ET AL., "Generation of cDNA Probes Directed by Amino Acid Sequence: Cloning of Urate Oxidase," Science, Vol. 239, p. 1288-1291, (1988).	X
	C7	MATTHEWS ET AL., "Biochemistry," The Benjamin /Cummings Publ. Co., Inc. (Redwood City, CA), p. 156-161, (1990).	X
	C8	NGUYEN ET AL., "Evaluation of the Role of Conseved His and Met Residues Among Lipoxygenases by Site-Directed Mutagenesis of Recombinant Human 5-Lipoxygenase," J. Biol. Chem., Vol. 266 (No. 32), p. 22057-22062, (1991).	X
	C9	REDDY ET AL., "Expression, Purification, and Characterization of Porvine Leukocyte 12-Lipoxygenase Produced in teh Methylootropic Yeast, Pichia Pastoris," Biochem. Biophys. Res. Comm., Vol. 205 ( No. 1), p. 381-388, ( November 30, 1994).	X
	C10	MARRA ET AL., "GenBank, Accession No. AA117154."	X
	C11	NCI-CGAP, "GenBank, Accession No. AA470333."	X

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.